2008 Drug Discovery for Neurodegeneration Conference

Washington, DC - February 4-5, 2008

Park Hyatt Washington DC

Presented by the Alzheimer's Drug Discovery Foundation

General Information   Speakers   Program    Accommodations   Registration   Sponsorship   Supporters

PROGRAM

NEW Click here to access the webcast of this program.

FEBRUARY 4, 2008

8:00 – 8:45 am

Registration & Continental Breakfast

8:45 – 9:00

Welcome & Opening Remarks

Howard Fillit, MD, Executive Director, ADDF

9:00 – 9:30

Plenary Talk: An Overview of Drug Discovery for Neurodegenerative Disease

Jeffrey S. Nye, MD, PhD, Vice President, Experimental Medicine, Johnson and Johnson Pharmaceutical R&D, LLC  (confirmed)

I. Target Identification & Validation: How Our Understanding of the Biology of Neurodegeneration Can Be Employed

Chair: Peter Reinhart, PhD, Wyeth Research  (confirmed)

9:30 – 9:35

Session Overview - Peter Reinhart, PhD

9:35 – 10:00

Mechanisms of Neurodegeneration that are Drugable: A Pharmaceutical Perspective

    Peter Reinhart, PhD, Wyeth Research (confirmed)

10:00 – 10:25

Novel Targets for CNS Drug Discovery: an Academic Perspective

   Linda Van Eldik, PhD, Northwestern University (confirmed)

10:25 – 10:40

BREAK

10:40 – 11:05

Target Validation in CNS Drug Discovery

    Barbara Sahagan, PhD, Pfizer, Inc. (confirmed)

11:05 – 11:35

Q & A

II. Lead Identification & Optimization: Unique Aspects of Chemistry in Neurodegenerative Disease

Chair: D. Martin Watterson, PhD, Northwestern University (confirmed)

11:35 – 11:40

Session Overview - D. Martin Watterson, PhD

11:40 – 12:05

Hits to Leads to Drugs: What Makes a Chemical a Drug

    Christopher A. Lipinski, PhD, Melior Discovery (confirmed)

12:05 – 12:30 pm

Rational Design and Medicinal Chemistry Refinement in CNS Drug Discovery: Principles and Case Studies

    Richard Silverman, PhD, Northwestern University (confirmed)

12:30 – 1:30

LUNCH

1:30 – 1:55

From Inhibitor to CNS Drug: Case Study of Secretase Inhibitors

    Jordan Tang, PhD, Oklahoma Medical Research Foundation (confirmed)

1:55 – 2:20

Biologics as Therapeutics: Special Issues

    Peter Seubert, PhD, Elan Pharmaceuticals (confirmed)

2:20 – 2:50

Q & A

III. Lead Discovery: In-Vitro Models of Neurodegenerative Disease

Chair: Ross Stein, PhD, Harvard Medical School & Brigham and Women’s Hospital (confirmed)

2:50 – 2:55

Session Overview - Ross Stein, PhD

2:55 – 3:20

Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates

   Christopher Moxham, PhD, Merck Research Laboratories (confirmed)

3:20 – 3:35

BREAK

3:35 – 4:00

Identification of Hits and Leads for Neurodegenerative Diseases

   Marcie Glicksman, PhD, Harvard Medical School (confirmed)

4:00 – 4:25

High-Throughput Screening in Academia: Program Development & Technology

   Jill Heemskerk, PhD, National Institute of Neurological Disorders and Stroke (confirmed)

4:25 – 4:55

Q & A

4:55 – 5:00

Closing Remarks

   Howard Fillit, MD, Executive Director, ADDF

5:00 – 7:00

NETWORKING RECEPTION

FEBRUARY 5, 2008

8:00 – 8:30 am

Continental Breakfast

8:30 – 8:40

Welcome & Opening Remarks

   Suzana Petanceska, PhD, National Institute on Aging (confirmed)                    

IV. Pre-Clinical Proof-of-Concept & Development: Neurodegenerative Disease

Chair: Jordan Tang, PhD, Oklahoma Medical Research Foundation (confirmed)

8:40 – 8:45

Session Overview - Jordan Tang, PhD

8:45 – 9:10

Characteristics of Compounds that Cross the Blood Brain Barrier  

   Douglas Spracklin, PhD, Pfizer Global Research and Development (confirmed)

9:10 – 9:35

Requirements for a Lead Compound to Become a Clinical Candidate   

   Franz Hefti, PhD, Avid Radiopharmaceuticals (confirmed)

9:35 – 10:00

What is Pre-Clinical Proof-of-Concept in Neurodegenerative Disease

   Wayne Rowe, PhD, Memory Pharmaceuticals (confirmed)

10:00 – 10:15

BREAK

10:15 – 10:40

 

The Basics of Pre-clinical Development

   Edward Spack, PhD, SRI International (confirmed)

10:40 – 11:10

Q & A

V. Resources and Services For Advancing Drug Discovery

Chair: Neil Buckholtz, PhD, National Institute on Aging (confirmed)

11:10 am – 11:15 pm

Session Overview - Neil Buckholtz, PhD

11:15 – 11:40

Services for Early Drug Discovery

    Duncan Beniston, Chembridge Corporation (confirmed)

11:40 am – 12:05 pm

Resources at the National Institute of Health

    Neil Buckholtz, PhD, National Institute on Aging (confirmed) and

    Lorenzo Refolo, PhD, National Institute of Neurological Disorders and Stroke (confirmed)

12:05 – 1:00

LUNCH

1:00 – 1:25

Academic Models of Drug Discovery Services

    Elias Michaelis, MD, PhD, University of Kansas (confirmed)

1:25 – 1:50

The FDA and Neurodegenerative Disease

    Robert Powell, Food and Drug Administration (FDA) (confirmed)

1:50 – 2:20

Q & A

2:20 – 2:35

BREAK

VI.  Disease specific issues in Drug Discovery for Neurodegenerative Disease

Chair: Elias Michaelis, MD, PhD, University of Kansas (confirmed)

2:35 – 2:40

Session Overview - Elias Michaelis, MD, PhD

2:40 – 3:40

Alzheimer’s disease

   Facilitators – Frank Longo, MD, PhD, Stanford University (confirmed)

                          Barry Greenberg, PhD, Neurochem, Inc. (confirmed)

 

Parkinson’s disease

   Facilitators – Todd Sherer, PhD, Michael J. Fox Foundation (confirmed)

                          Kalpana Merchant, PhD, Eli Lilly and Company (confirmed)

 

Huntington’s disease

   Facilitators – Pierre Goloubinoff, PhD, University of Lausanne (confirmed) and

                          Robert Elfont, MD, PhD (confirmed)

 

Amyotrophic Lateral Sclerosis

    Facilitators – Jeffrey Rothstein, MD, PhD, Johns Hopkins University (confirmed)

                          and Kenneth J. Rhodes, PhD, Biogen Idec, Inc. (confirmed)

 

'Orphan’ Neurological Diseases

    Facilitators – Kim Hunter-Schaedle, PhD, Children’s Tumor Foundation (confirmed)

                           Kate Haviland, PTC Therapeutics (confirmed)                       

3:40 – 4:35

Group Presentations

4:35 – 4:45

Closing Remarks

 Howard Fillit, MD, Executive Director, ADDF

top